Banque Transatlantique Sa Alnylam Pharmaceuticals, Inc. Transaction History
Banque Transatlantique Sa
- $5.69 Billion
- Q1 2025
A detailed history of Banque Transatlantique Sa transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Banque Transatlantique Sa holds 29 shares of ALNY stock, worth $8,408. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29Holding current value
$8,408% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
720Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$4.86 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$3.79 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.77 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.07 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.28 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $35.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...